Charles Koch
President @ Koch Disruptive Technologies
Wichita, United States
Charles Koch is a Series D investor at Koch Disruptive Technologies in Wichita focused on Health Care and Medical Device. Charles Koch is chairman of the board and CEO of Koch Industries, Inc., a position he has held since 1967.Since then, the company has been transformed into a dynamic and diverse group of companies with more than 100,000 employees and a presence in about 60 countries. Since 2003, Koch companies have invested about $60 billion in acquisitions andother capital expenditures. Based in Wichita, Kan., Koch Industries is involved in refining, chemicals and biofuels; forest and consumer products; fertilizers; polymers and fibers; process and pollution control equipment and technologies; electronic components, commodity trading; minerals; energy; ranching; glass; and investments. Familiar Koch companies’ brands include STAINMASTER® carpet, LYCRA® fiber, Quilted Northern® tissue, and the Dixie® brand of cups, plates and cutlery. Much of Koch Industries' success can be traced to Mr. Koch's interest in and commitment to scientific and social progress, which led to the development and implementation of Market-Based Management® business philosophy. The concepts and practice of MBM® are described in Mr. Koch’s book, “The Science of Success,” published in February 2007 by John Wiley & Sons, Inc. Mr. Koch is further developing the theories and expanding the practice of the MBM philosophy, as well as other applications of the science of human action, not only throughout Koch Industries, but also with scholars, non-profit leaders, government officials and other business leaders.He has continuously supported academic and public policy research (including a number of Nobel Prize winners) for 50 years, with a special focus on developing voluntary, market-based solutions to social problems. This interest led Mr. Koch to found or help build a number of organizations, including the Institute for Humane Studies, Cato Institute, Mercatus Center at George Mason University, Bill of Rights Institute, and Market-Based Management Institute.Mr. Koch received a bachelor’s degree in general engineering (1957) and two master’s degrees in nuclear and chemical engineering (1958 and 1959, respectively) from the Massachusetts Institute of Technology. His employment has been as an engineer, Arthur D. Little, Inc. 1959-61; vice president, Koch Engineering Company, Inc. 1961-63, president, 1963-71; president, Koch Industries, Inc. 1966-74; chairman and chief executive officer, 1967- present. He was born in Wichita, Kansas. Mr. Koch and his wife of 41 years, Liz, have two children.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Charles Koch invests in
Stages Charles Koch invests in
Countries Charles Koch invests in
Investment Focus
Industry
- Health Care 2 (100%)
- Medical Device 2 (100%)
- Medical 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series D 1 (50%)
- Series F 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sight Diagnostics
|
Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science.Sight’s firstproduct, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents.*Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US. | $71M / Series D / Aug 05, 2020 | |
InSightec
|
InSightec is the pioneer and global leader in MR guided focused ultrasound technology for image guided acoustic surgery.ExAblate® 2000 system was the first system to use the MR guided focused ultrasound technology. The ExAblate system received CE mark in 2002 and the Food and Drug Administration (FDA) approval in 2004 for the treatment ofsymptomatic uterine fibroids. ExAblate received the European CE Mark for pain palliation of bone metastases in June 2007 and for adenomyosis in June 2010. This device has won numerous innovation awards and has been used to treat thousands of patients around the world. | $150M / Series F / Mar 06, 2020 |
Co-Investors
About Koch Disruptive Technologies
Founded in November 2017 upon the spirit of transformation, Koch Disruptive Technologies (KDT) originates and invests in promising entrepreneurs and technologies across industries to improve Koch Industries' existing businesses and create new opportunities.Based in Wichita, Kansas, Koch Industries, Inc. is one of the largest privatecompanies in America with estimated annual revenues as high as $100 billion, according to Forbes. It owns a diverse group of companies involved in refining, chemicals, and biofuels; forest and consumer products; fertilizers; polymers and fibers; process and pollution control equipment and technologies; electronics; information systems; commodity trading; minerals; energy; glass; ranching; and investments. Since 2003, Koch companies have invested more than $80 billion in acquisitions and other capital expenditures. With a presence in about 60 countries, Koch companies employ more than 120,000 people worldwide, with about 70,000 of those in the United States. From January 2009 to present, Koch companies have earned more than 1,200 awards for safety, environmental excellence, community stewardship, innovation, and customer service.Learn more about KDT at http://news.kochind.com/news/2017/koch-disruptive-technologies-ready-to-transform
Koch Disruptive Technologies Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jason Illian
Managing Director
|
|||
|
Charles Koch
President
|
|||
Charles Koch
President
|
|||
David M. Mauney
Managing Director
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Charles Koch invest in?
Charles Koch invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Series F stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Charles Koch last invest?
The most recent investment recorded for Charles Koch closed in Aug 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
